Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market
Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size, Share & Trends Analysis Report, By Drugs (Talazoparib, Veliparib, Olaparib, and Others), By Indication (Ovarian Cancer, Fallopian Tube Cancer, Breast Cancer, and Others), Forecast Period (2026-2035)
Industry Overview
Poly (ADP-Ribose) polymerase (PARP) inhibitors market was valued at $4.0 billion in 2025 and is projected to reach $9.37 billion by 2035, growing at a CAGR of 8.8 % during the forecast period 2026-2035. Rising utilization of PARP inhibitors in targeted cancer therapies, including ovarian, breast, and prostate cancers, is driving growth in the global market. Precision medicine and expanded genetic testing have made it possible to identify patients who are most likely to benefit from these treatments, increasing clinical adoption. Research into combination therapies and innovative treatment regimens is creating additional opportunities for market expansion. Regulatory approvals across multiple regions are facilitating wider access and supporting physician confidence. Awareness of personalized oncology approaches among healthcare providers and patients is encouraging broader uptake.
Market Dynamics
Expansion of Targeted Oncology Applications
The application of PARP inhibitors is increasingly extending beyond traditional ovarian and breast cancers into prostate, pancreatic, and other solid tumors. Growing understanding of genetic mutations and DNA repair deficiencies has enabled clinicians to identify patient populations that are likely to benefit from PARP-targeted therapies. Clinical studies investigating combination regimens with chemotherapy, immunotherapy, and other targeted agents are further expanding therapeutic possibilities. Adoption of these inhibitors is being reinforced by evidence demonstrating improved patient outcomes and progression-free survival. Pharmaceutical companies are actively pursuing label expansions and region-specific approvals, driving broader market penetration.
Advancements in Diagnostic and Companion Testing
Integration of companion diagnostic tools is playing a critical role in guiding PARP inhibitor therapy and enhancing treatment personalization. Improved accessibility of genetic and biomarker testing allows for more precise patient selection, increasing treatment efficacy and reducing unnecessary exposure. Technological advancements in next-generation sequencing and cost-effective testing platforms are supporting faster adoption in both developed and emerging markets. Partnerships between diagnostics and pharmaceutical companies are facilitating streamlined workflows for clinicians. Regulatory bodies are increasingly recognizing and approving companion diagnostics alongside drug therapies, which strengthens market confidence.
Market Segmentation
- Based on the drug, the market is segmented into talazoparib, veliparib, olaparib and others.
- Based on the indication, the market is segmented into ovarian cancer, fallopian tube cancer, breast cancer and others.
Olaparib Segment to Lead the Market with the Largest Share
Extensive clinical adoption of Olaparib is significantly contributing to the growth of the global Poly (ADP-Ribose) Polymerase (PARP) inhibitors market. Its established efficacy in treating ovarian, breast, and other BRCA-mutated cancers has reinforced its position as a preferred therapeutic option. Regulatory approvals across multiple regions have facilitated broader patient access and increased market penetration. Continued research into combination therapies and expanded indications is further driving demand. Growing awareness among healthcare providers and patients about targeted cancer therapies is supporting uptake.
Ovarian Cancer: A Key Segment in Market Growth
Rising incidence of ovarian cancer is driving growth in the global PARP inhibitors market as these therapies offer targeted treatment options for patients with BRCA mutations and homologous recombination deficiencies. Increasing adoption of maintenance therapy following chemotherapy has reinforced clinical use and supported long-term treatment strategies. Advancements in genetic testing and biomarker identification have enabled more precise patient selection, enhancing therapeutic outcomes and clinician confidence. Regulatory approvals for multiple indications in ovarian cancer across major markets have expanded accessibility and treatment adoption. Ongoing clinical trials exploring combination therapies and extended indications continue to generate interest among healthcare providers.
Regional Outlook
The global Poly (ADP-Ribose) Polymerase (PARP) inhibitors market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
Rising Adoption of Precision Oncology Treatments in Europe
Rising adoption of precision oncology treatments is driving growth in the European PARP inhibitors market, particularly for patients with ovarian, breast, and prostate cancers. Expansion of genetic testing and biomarker screening has enabled clinicians to identify suitable candidates for targeted therapy, improving treatment outcomes. Regulatory approvals across multiple European countries have increased access to these therapies, while reimbursement support in key markets encourages wider clinical use. Ongoing clinical trials exploring combination therapies and new indications continue to generate interest among healthcare providers. Increased awareness of personalized medicine approaches among physicians and patients is further supporting uptake.
North America Region Dominates the Market with Major Share
Increasing demand for targeted cancer therapies is driving growth in the North American PARP inhibitors market, particularly in ovarian, breast, and prostate cancers. High adoption of genetic testing and biomarker-driven treatment strategies has enabled clinicians to identify patients most likely to benefit from PARP inhibition, supporting broader clinical use. Expansion of maintenance therapy options following chemotherapy has further reinforced uptake in oncology centers. Regulatory approvals across the United States and Canada have improved accessibility and clinician confidence in these therapies. Ongoing clinical trials exploring combination regimens and new indications continue to generate interest in the region.
Market Players Outlook
The major companies operating in the global Poly (ADP-Ribose) Polymerase (PARP) inhibitors market include AstraZeneca, Cipla Ltd., Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline and Pfizer Inc., among others. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In August 2025, Allarity Therapeutics, Inc. announced that the U.S. Food and Drug Administration had granted fast-track designation for its investigational PARP and WNT pathway inhibitor, stenoparib, for the treatment of advanced ovarian cancer.
- In January 2025, IMPACT Therapeutics announced that its PARP inhibitor Senaparib had received marketing authorization from the Chinese National Medical Products Administration (NMPA) for use as a first-line maintenance treatment in patients with advanced ovarian cancer. The approval allows the product to be commercially available for this specific indication in China.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Poly (ADP-Ribose) Polymerase (PARP) inhibitors Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
TABLE OF CONTENTS
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Sales Analysis – Drugs| Indication| ($ Million)
- Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Revenue and Share by Manufacturers
- Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- AstraZeneca
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Cipla Ltd.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Reddy’s Laboratories Ltd.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- GlaxoSmithKline
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Pfizer Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- AstraZeneca
- Key Company Analysis
- Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Sales Analysis by Drugs ($ Million)
- Talazoparib
- Veliparib
- Olaparib
- Others
- Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Sales Analysis by Indication ($ Million)
- Ovarian Cancer
- Fallopian Tube Cancer
- Breast Cancer
- Others
- Regional Analysis
- North American Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Sales Analysis – Drugs| Indication| Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Sales Analysis – Drugs| Indication| Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Sales Analysis – Drugs| Indication| Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Sales Analysis – Drugs| Indication| Country ($ Million)
- Macroeconomic Factors for Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- Allieva Pharma Pvt. Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Aprazer Healthcare Pvt Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AstraZeneca
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- BeOne Medicines Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Biofiya Healthcare
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Cipla Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Reddy’s Laboratories Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Eris Life Sciences Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- GlaxoSmithKline
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Glenmark Pharmaceuticals Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Hetero Labs Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Intas Pharmaceuticals Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Jiangsu Hengrui Pharmaceutical Co., Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Johnson & Johnson Co. (Janssen Biotech, Inc.)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Natco Pharma Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sun Pharmaceutical Industries Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Tolmar, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Zuvius Lifesciences Pvt. Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Zydus Lifesciences Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Allieva Pharma Pvt. Ltd.
1. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Research and Analysis by Type, 2025–2035 ($ Million)
2. Global Talazoparib Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Veliparib Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Olaparib Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global Others Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Research and Analysis by Indication, 2025–2035 ($ Million)
7. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors For Ovarian Cancer Market Research and Analysis by Region, 2025–2035 ($ Million)
8. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors For Fallopian Tube Cancer Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors For Breast Cancer Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors For Other Indications Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Research and Analysis by Region, 2025–2035 ($ Million)
12. North American Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Research and Analysis by Country, 2025–2035 ($ Million)
13. North American Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Research and Analysis by Type, 2025–2035 ($ Million)
14. North American Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Research and Analysis by Indication, 2025–2035 ($ Million)
15. European Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Research and Analysis by Country, 2025–2035 ($ Million)
16. European Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Research and Analysis by Type, 2025–2035 ($ Million)
17. European Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Research and Analysis by Indication, 2025–2035 ($ Million)
18. Asia-Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Research and Analysis by Country, 2025–2035 ($ Million)
19. Asia-Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Research and Analysis by Type, 2025–2035 ($ Million)
20. Asia-Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Research and Analysis by Indication, 2025–2035 ($ Million)
21. Rest of the World Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Research and Analysis by Region, 2025–2035 ($ Million)
22. Rest of the World Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Research and Analysis by Type, 2025–2035 ($ Million)
23. Rest of the World Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Research and Analysis by Indication, 2025–2035 ($ Million)
1. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Share by Type, 2025 Vs 2035 (%)
2. Global Talazoparib Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Share by Region, 2025 Vs 2035 (%)
3. Global Veliparib Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Share by Region, 2025 Vs 2035 (%)
4. Global Olaparib Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Share by Region, 2025 Vs 2035 (%)
5. Olaparib Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Share by Region, 2025 Vs 2035 (%)
6. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Share by Indication, 2025 Vs 2035 (%)
7. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors For Ovarian Cancer Market Share by Region, 2025 Vs 2035 (%)
8. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors For Fallopian Tube Cancer Market Share by Region, 2025 Vs 2035 (%)
9. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors For Breast Cancer Market Share by Region, 2025 Vs 2035 (%)
10. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors For Other Indications Market Share by Region, 2025 Vs 2035 (%)
11. Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Research and Analysis by Region, 2025–2035 ($ Million)
12. US Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size, 2025–2035 ($ Million)
13. Canada Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size, 2025–2035 ($ Million)
14. UK Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size, 2025–2035 ($ Million)
15. France Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size, 2025–2035 ($ Million)
16. Germany Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size, 2025–2035 ($ Million)
17. Italy Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size, 2025–2035 ($ Million)
18. Spain Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size, 2025–2035 ($ Million)
19. Russia Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size, 2025–2035 ($ Million)
20. Rest of Europe Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size, 2025–2035 ($ Million)
21. India Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size, 2025–2035 ($ Million)
22. China Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size, 2025–2035 ($ Million)
23. Japan Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size, 2025–2035 ($ Million)
24. South Korea Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size, 2025–2035 ($ Million)
25. Australia and New Zealand Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size, 2025–2035 ($ Million)
26. ASEAN Economies Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size, 2025–2035 ($ Million)
27. Rest of Asia-Pacific Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size, 2025–2035 ($ Million)
28. Latin America Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size, 2025–2035 ($ Million)
29. Middle East and Africa Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
